T2 Biosystems (TTOO)
(Delayed Data from NSDQ)
$2.05 USD
-0.01 (-0.49%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $2.06 +0.01 (0.49%) 5:26 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.05 USD
-0.01 (-0.49%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $2.06 +0.01 (0.49%) 5:26 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Company News for May 26, 2020
by Zacks Equity Research
Companies In The News Are: TTWO, XERS, SPLK, NAVB
Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
Analysts Estimate T2 Biosystems (TTOO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: T2 Biosystems (TTOO) Q3 Earnings Expected to Decline
by Zacks Equity Research
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
T2 Biosystems (TTOO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
T2 Biosystems (TTOO) delivered earnings and revenue surprises of -9.38% and -10.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
T2 Biosystems (TTOO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
T2 Biosystems (TTOO) delivered earnings and revenue surprises of -13.33% and 31.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.
T2 Biosystems (TTOO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
T2 Biosystems (TTOO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
by Zacks Equity Research
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
4 Medical Device Stocks to Top Q3 Earnings
by Zacks Equity Research
A look at how medical device players are poised for this earnings season.
5 Medtech Stocks to Steer Clear of Amid Political Chaos
by Zacks Equity Research
In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.
Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner
MedTech Industry Outlook - March 2017
by Zacks Equity Research
A shrinking customer base indicates an impending slash in the demand for expensive medical procedures and devices.
5 MedTech Stocks Poised to Trump Earnings in Q4
by Zacks Equity Research
MedTech's steady earnings trend reflects a strong product cycle and continuing innovation.